358 related articles for article (PubMed ID: 24313320)
1. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
Patterson H; Nibbs R; McInnes I; Siebert S
Clin Exp Immunol; 2014 Apr; 176(1):1-10. PubMed ID: 24313320
[TBL] [Abstract][Full Text] [Related]
2. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
3. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
4. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors.
Bonilla-Hernán MG; Miranda-Carús ME; Martin-Mola E
Rheumatology (Oxford); 2011 Sep; 50(9):1542-50. PubMed ID: 21622522
[TBL] [Abstract][Full Text] [Related]
5. Novel small molecule therapeutics in rheumatoid arthritis.
Kelly V; Genovese M
Rheumatology (Oxford); 2013 Jul; 52(7):1155-62. PubMed ID: 23297340
[TBL] [Abstract][Full Text] [Related]
6. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
7. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II-induced migration of vascular smooth muscle cells is mediated by p38 mitogen-activated protein kinase-activated c-Src through spleen tyrosine kinase and epidermal growth factor receptor transactivation.
Mugabe BE; Yaghini FA; Song CY; Buharalioglu CK; Waters CM; Malik KU
J Pharmacol Exp Ther; 2010 Jan; 332(1):116-24. PubMed ID: 19797620
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
12. [Involvement of Syk in pathology of systemic autoimmune disease].
Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Saito K; Akashi K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):56-61. PubMed ID: 22374444
[TBL] [Abstract][Full Text] [Related]
13. Kinase inhibitors: a new class of antirheumatic drugs.
Kyttaris VC
Drug Des Devel Ther; 2012; 6():245-50. PubMed ID: 23055694
[TBL] [Abstract][Full Text] [Related]
14. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
Lin YC; Huang DY; Chu CL; Lin WW
Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
[TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
17. Endothelin-1 induces contraction via a Syk-mediated p38 mitogen-activated protein kinase pathway in rat aortic smooth muscle.
Lee HM; Won KJ; Kim J; Park HJ; Kim HJ; Roh HY; Lee SH; Lee CK; Kim B
J Pharmacol Sci; 2007 Apr; 103(4):427-33. PubMed ID: 17409631
[TBL] [Abstract][Full Text] [Related]
18. Selective pharmacological inhibitors reveal the role of Syk tyrosine kinase, phospholipase C, phosphatidylinositol-3'-kinase, and p38 mitogen-activated protein kinase in Fc receptor-mediated signaling of chicken heterophil degranulation.
Kogut M; Lowry VK; Farnell M
Int Immunopharmacol; 2002 Jun; 2(7):963-73. PubMed ID: 12188037
[TBL] [Abstract][Full Text] [Related]
19. Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinase.
Hall J; Aulabaugh A; Rajamohan F; Liu S; Kaila N; Wan ZK; Ryan M; Magyar R; Qiu X
J Biol Chem; 2012 Mar; 287(10):7717-27. PubMed ID: 22219190
[TBL] [Abstract][Full Text] [Related]
20. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
Yazici Y; Regens AL
Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
